Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V 1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
The limbic localization of the arginine vasopressin V 1b receptor has prompted speculation as to a potential role of this receptor in the control of emotional processes. To investigate this possibility, we have studied the behavioral effects of SSR149415, the first selective and orally active non-peptide antagonist of vasopressin V 1b receptors, in a variety of classical (punished drinking, elevated plus-maze, and light/dark tests) and atypical (fear/anxiety defense test battery and social defeat-induced anxiety) rodent models of anxiety, and in two models of depression [forced swimming and chronic mild stress (CMS)]. When tested in classical tests of anxiety, SSR149415 produced anxiolytic-like activity at doses that ranged from 1 to 30 mg/kg (i.p. or p.o.), but the magnitude of these effects was overall less than that of the benzodiazepine anxiolytic diazepam, which was used as a positive control. In contrast, SSR149415 produced clear-cut anxiolytic-like activity in models involving traumatic stress exposure, such as the social defeat paradigm and the defense test battery (1–30 mg/kg, p.o.). In the forced swimming test, SSR149415 (10–30 mg/kg, p.o.) produced antidepressant-like effects in both normal and hypophysectomized rats. Moreover, in the CMS model in mice, repeated administration of SSR149415 (10 and 30 mg/kg, i.p.) for 39 days improved the degradation of the physical state, anxiety, despair, and the loss of coping behavior produced by stress. These findings point to a role for vasopressin in the modulation of emotional processes via the V 1b receptor, and suggest that its blockade may represent a novel avenue for the treatment of affective disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat
Pellow, S., Chopin, P., File, S. E., & Briley, M. (1985) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(85)90031-7 · Cited by 5,822
Depression: a new animal model sensitive to antidepressant treatments
PORSOLT, R. D., LE PICHON, M., & JALFRE, M. (1977) · Nature · doi:10.1038/266730a0 · Cited by 4,451
Neurocircuitry of stress: central control of the hypothalamo–pituitary–adrenocortical axis
Herman, J. P., & Cullinan, W. E. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10069-2 · Cited by 2,270
Chronic mild stress-induced anhedonia: A realistic animal model of depression
Willner, P., Muscat, R., & Papp, M. (1992) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(05)80194-0 · Cited by 1,160
A simple and reliable conflict procedure for testing anti-anxiety agents
Vogel, J. R., Beer, B., & Clody, D. E. (1971) · Psychopharmacologia · doi:10.1007/bf00403989 · Cited by 841
Ethopharmacological analysis of rat behavior on the elevated plus-maze
Cruz, A. P. M., Frei, F., & Graeff, F. G. (1994) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)90472-3 · Cited by 823
de Vries, G. J., & Buijs, R. M. (1983) · Brain Research · doi:10.1016/0006-8993(83)90855-7 · Cited by 565
Molecular cloning and expression of a rat Via arginine vasopressin receptor
Morel, A., O'Carroll, A.-M., Brownstein, M. J., & Lolaft, S. J. (1992) · Nature · doi:10.1038/356523a0 · Cited by 477
Animal models for the study of anti-anxiety agents: A review
Treit, D. (1985) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(85)90046-6 · Cited by 450
Miczek, K. A. (1979) · Psychopharmacology · doi:10.1007/bf00426664 · Cited by 397
Research works printed but not linked: 3
- D De Wied J Endocrinol 48, xlv–xlvi (1970).
- R Dantzer, R M Bluthe Crit Rev Neurobiol 6, 243–255 (1992).
- J Simiand, P E Keane, M C Barnouin, M Keane, P Soubrié, G Le Fur Fundam Clin Pharmacol 7, 413–427 (1993).
Cited by
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321
The HPA axis in major depression: classical theories and new developments
Pariante, C. M., & Lightman, S. L. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.006 · Cited by 2,009
Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine
Meyer-Lindenberg, A., Domes, G., Kirsch, P., & Heinrichs, M. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3044 · Cited by 1,688
“Because a selective AVPR1B antagonist had anxiolytic- and antidepressant-like effects in rodent”
BackgroundWillner, P. (2005) · Neuropsychobiology · doi:10.1159/000087097 · Cited by 1,605
Fatigue in neurological disorders
Chaudhuri, A., & Behan, P. O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15794-2 · Cited by 1,297
David, D. J., Samuels, B. A., Rainer, Q., Wang, J.-W., Marsteller, D., Mendez, I., Drew, M., Craig, D. A., Guiard, B. P., Guilloux, J.-P., et al. (2009) · Neuron · doi:10.1016/j.neuron.2009.04.017 · Cited by 1,267
“This measure has been described as a reliable and well-validated index of a depressed-like state (Griebel et al., 2002; Santarelli et al., 2003).”
BackgroundThe ascent of mouse: advances in modelling human depression and anxiety
Cryan, J. F., & Holmes, A. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1825 · Cited by 1,198
Landgraf, R., & Neumann, I. D. (2004) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2004.05.001 · Cited by 1,059
Sucrose preference test for measurement of stress-induced anhedonia in mice
Liu, M.-Y., Yin, C.-Y., Zhu, L.-J., Zhu, X.-H., Xu, C., Luo, C.-X., Chen, H., Zhu, D.-Y., & Zhou, Q.-G. (2018) · Nature Protocols · doi:10.1038/s41596-018-0011-z · Cited by 1,026
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
Vasopressin and Oxytocin Excite Distinct Neuronal Populations in the Central Amygdala
Huber, D., Veinante, P., & Stoop, R. (2005) · Science · doi:10.1126/science.1105636 · Cited by 804
Schmidt, H. D., & Duman, R. S. (2007) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282ee2aa8 · Cited by 648
“Recent studies, however, have shown that chronic antidepressant treatments improve the physical state of mice exposed to CMS/CUS (Griebel et al., 2002; Ducottet et al., 2003).”
BackgroundInfluentialCryan, J. F., & Mombereau, C. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001457 · Cited by 616
Surget, A., Saxe, M., Leman, S., Ibarguen-Vargas, Y., Chalon, S., Griebel, G., Hen, R., & Belzung, C. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.02.022 · Cited by 556
Self-citationThe Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Bielsky, I. F., Hu, S.-B., Szegda, K. L., Westphal, H., & Young, L. J. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300360 · Cited by 531
“Treatment with a novel, orally active V1b antagonist resulted in reduced anxietyrelated behavior while characterization of a V1b knockout mouse found no difference in anxiety-related behavior, but mildly impaired social recognition (Griebel et al, 2002; Wersinger et al, 2002).”
BackgroundVasopressin: Behavioral roles of an “original” neuropeptide
Caldwell, H. K., Lee, H.-J., Macbeth, A. H., & Young, W. S. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.10.007 · Cited by 504
“Effects of hypophysectomy have been mixed; in one study, hypophysectomy did not alter the anxiolytic effects of the Avpr1b antagonist (Griebel et al., 2002), while in another study hypophysectomy blocked those effects (Shimazaki et al., 2006).”
BackgroundResultInfluentialNeural Mechanisms of Stress Resilience and Vulnerability
Franklin, T. B., Saab, B. J., & Mansuy, I. M. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.016 · Cited by 500
Stress Hormone Regulation: Biological Role and Translation into Therapy
Holsboer, F., & Ising, M. (2010) · Annual Review of Psychology · doi:10.1146/annurev.psych.093008.100321 · Cited by 473
“In standard tests, such as the elevated plus maze (discussed above), it produced anxiolytic-like effects, which were particularly pronounced in models of traumatic stress exposure (Griebel et al. 2002).”
BackgroundA trans-dimensional approach to the behavioral aspects of depression
Bessa, J. M. (2009) · Frontiers in Behavioral Neuroscience · doi:10.3389/neuro.08.001.2009 · Cited by 469
“Consistent with previous work (Griebel et al., 2002a; Song et al., 2006), the present experiments demonstrated the effi cacy of tricyclic agents (e.g. imipramine) and selective serotonin reuptake inhibitors (SSRI; e.g. fl uoxetine) in reversing the anhedonic and helpless behaviors that develop…”
BackgroundResultEffects of unpredictable chronic mild stress on anxiety and depression-like behavior in mice
Mineur, Y. S., Belzung, C., & Crusio, W. E. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.07.029 · Cited by 459
Pryce, C. R., Rüedi-Bettschen, D., Dettling, A. C., Weston, A., Russig, H., Ferger, B., & Feldon, J. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.011 · Cited by 414
Vasopressin V1a and V1b Receptors: From Molecules to Physiological Systems
Koshimizu, T.-A., Nakamura, K., Egashira, N., Hiroyama, M., Nonoguchi, H., & Tanoue, A. (2012) · Physiological Reviews · doi:10.1152/physrev.00035.2011 · Cited by 407
“) and antidepressant-like (in forced swimming and chronic mild stress tests) effects in rodents (186).”
BackgroundNeuropeptide systems as novel therapeutic targets for depression and anxiety disorders
Holmes, A., Heilig, M., Rupniak, N. M. J., Steckler, T., & Griebel, G. (2003) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2003.09.011 · Cited by 403
Self-citationPothion, S., Bizot, J.-C., Trovero, F., & Belzung, C. (2004) · Behavioural Brain Research · doi:10.1016/j.bbr.2004.04.008 · Cited by 400
“As it was previously suggested, this behavioural alteration may reflect the reduction of the efficiency with which even the smallest tasks are accomplished in depressed patients, leading to the inability to maintain minimal personal hygiene [12].”
BackgroundMethodInfluentialNon-peptide arginine-vasopressin antagonists: the vaptans
Decaux, G., Soupart, A., & Vassart, G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60695-9 · Cited by 376
Bielsky, I. F., Hu, S.-B., Ren, X., Terwilliger, E. F., & Young, L. J. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.031 · Cited by 367
Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development
Koob, G. F. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000083 · Cited by 337
“A small-molecule V1b receptorantagonist exertedanxiolytic- andantidepressantlike effects (Griebel et al., 2002), with a focus on sites of action in the basolateral amygdala, CeA, medial amygdala (Salomé et al., 2006), lateral septum (Stemmelin et al., 2005), and dorsal hippocampus (Engin and Treit,…”
BackgroundPathophysiology, diagnosis and management of nephrogenic diabetes insipidus
Bockenhauer, D., & Bichet, D. G. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.89 · Cited by 333
“Vasopressin (and oxytocin) act as neurotransmitters that modulate the autonomic fear response84 and vasopressin has been described to enhance aggressiveness, anxiety and stress levels in an animal model.(85) Raised”
BackgroundNeuropeptides: opportunities for drug discovery
Hökfelt, T., Bartfai, T., & Bloom, F. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00482-4 · Cited by 328
Alonso, R., Griebel, G., Pavone, G., Stemmelin, J., Le Fur, G., & Soubrié, P. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001464 · Cited by 319
Self-citationThe Vasopressin System: Physiology and Clinical Strategies
Treschan, T. A., Peters, J., & Warltier, D. C. (2006) · Anesthesiology · doi:10.1097/00000542-200609000-00026 · Cited by 316
MANNING, M., STOEV, S., CHINI, B., DURROUX, T., MOUILLAC, B., & GUILLON, G. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00437-8 · Cited by 296
The Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic
Blanchard, D. C., Griebel, G., & Blanchard, R. J. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01276-7 · Cited by 295
“Selective blockade of the V 1b receptor by the nonpeptide antagonist SSR149415 was shown to block restraint stress-induced ACTH release (Serradeil-Le Gal et al., 2002) and produce anxiolytic-like activity in several procedures (Griebel et al., 2002a).”
BackgroundSelf-citationBehavioral animal models of depression
Yan, H.-C., Cao, X., Das, M., Zhu, X.-H., & Gao, T.-M. (2010) · Neuroscience Bulletin · doi:10.1007/s12264-010-0323-7 · Cited by 294
“[89] Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, et al.”
Brenes Sáenz, J. C., Villagra, O. R., & Fornaguera Trías, J. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.12.001 · Cited by 290
Dabrowska, J., Hazra, R., Ahern, T. H., Guo, J.-D., McDonald, A. J., Mascagni, F., Muller, J. F., Young, L. J., & Rainnie, D. G. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.03.003 · Cited by 274
“Hence, AVP acts synergistically with CRF to activate HPA axis and has been shown to enhance anxiety and the consolidation of fear memory (Griebel et al., 2002; Caldwell et al., 2008), while OT acts as an anxiolytic in behavioral paradigms, and dampens the stress response (McCarthy et al., 1996;…”
High vs Low Anxiety-Related Behavior Rats: An Animal Model of Extremes in Trait Anxiety
Landgraf, R., & Wigger, A. (2002) · Behavior Genetics · doi:10.1023/a:1020258104318 · Cited by 274
“It remains to be shown to which extent V1a and V1b receptors ( Griebel et al., 2002 ) are involved in these phenomena.”
BackgroundWigger, A., Sánchez, M. M., Mathys, K. C., Ebner, K., Frank, E., Liu, D., Kresse, A., Neumann, I. D., Holsboer, F., Plotsky, P. M., et al. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300290 · Cited by 263
“Released centrally and interacting with V1a-R (Raggenbass et al, 1998) and V1b-R (Griebel et al, 2002), AVP is well known to be involved in multiple behavioral processes including cognition and emotionality (De Wied et al, 1988; Landgraf, 1995; Landgraf et al, 1995a; Engelmann et al, 1996; Liebsch…”
BackgroundMasi, G., & Brovedani, P. (2011) · CNS Drugs · doi:10.2165/11595900-000000000-00000 · Cited by 260
Tanoue, A., Ito, S., Honda, K., Oshikawa, S., Kitagawa, Y., Koshimizu, T., Mori, T., & Tsujimoto, G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19656 · Cited by 258
“Also, a “V1b receptor–selective” antagonist, SSR149415, has been recently developed, and pharmacological studies showed that it inhibits the exogenous AVP-induced increase in circulating ACTH and possesses anxiolytic- and antidepressant-like effects (13, 14).”
Blume, A., Bosch, O. J., Miklos, S., Torner, L., Wales, L., Waldherr, M., & Neumann, I. D. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06184.x · Cited by 255
“Intracerebral VP, which rather exerts anxiogenic actions within the brain (Griebel et al., 2002; Bielsky et al., 2004; Landgraf et al., 2007), seems to activate different, yet unknown, signalling mechanisms.”
BackgroundThe Endomorphin System and Its Evolving Neurophysiological Role
Fichna, J., Janecka, A., Costentin, J., & Do Rego, J.-C. (2007) · Pharmacological Reviews · doi:10.1124/pr.59.1.3 · Cited by 250
“…acute stress increased extracellular levels of AVP in the rat amygdala or hypothalamus (Ebner et al., 2002; Wigger et al., 2004) and the activation of V1 receptors by AVP may underlie anxiogenic and depressive behaviors in the rat (Liebsch et al., 1996; Griebel et al., 2002; Wigger et al., 2004).”
BackgroundEnantioselective Iron-Catalyzed Azidation of β-Keto Esters and Oxindoles
Deng, Q.-H., Bleith, T., Wadepohl, H., & Gade, L. H. (2013) · Journal of the American Chemical Society · doi:10.1021/ja402082p · Cited by 250
Ducottet, C., Griebel, G., & Belzung, C. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00051-4 · Cited by 236
“However, this result contrasts with other data showing an anxiogenic effect of the CMS (Griebel et al., 2002a,b).”
BackgroundResultInfluentialSelf-citationPichat, P., Bergis, O. E., Terranova, J.-P., Urani, A., Duarte, C., Santucci, V., Gueudet, C., Voltz, C., Steinberg, R., Stemmelin, J., et al. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301188 · Cited by 236
“The CMS protocol, originally described by Willner et al (1992) for rats, was adapted from the one described by Griebel et al (2002) for mice.”
MethodSelf-citationAnxiolytic-Like Properties of the Anandamide Transport Inhibitor AM404
Bortolato, M., Campolongo, P., Mangieri, R. A., Scattoni, M. L., Frau, R., Trezza, V., La Rana, G., Russo, R., Calignano, A., Gessa, G. L., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301061 · Cited by 231
“Some of the rats tested for conditioned place preference (CPP) were housed under enriched conditions, consisting in exposing the rats for 6 weeks to a varied set of daily exchanged toys in a structured cage environment, as well as daily handling sessions.”
BackgroundMethodModels of Depression: Unpredictable Chronic Mild Stress in Mice
Nollet, M., Guisquet, A. L., & Belzung, C. (2013) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph0565s61 · Cited by 228
“Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.”
Zhu, X.-H., Yan, H.-C., Zhang, J., Qu, H.-D., Qiu, X.-S., Chen, L., Li, S.-J., Cao, X., Bean, J. C., Chen, L.-H., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.6414-09.2010 · Cited by 227
“Also, coat state assay has been shown to be a good index of the response of rats to CMS (Griebel et al., 2002; Alonso et al., 2004), as this measure is rapidly observed and reproducible.”
InfluentialZhou, Q., Hu, Y., Hua, Y., Hu, M., Luo, C., Han, X., Zhu, X., Wang, B., Xu, J., & Zhu, D. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04914.x · Cited by 225
Young, W. S., Li, J., Wersinger, S. R., & Palkovits, M. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.08.040 · Cited by 222
“Pharmacological antagonism of the Avpr1b produces reduced anxiety and aggression (Griebel et al., 2002; Blanchard et al., 2005; Stemmelin et al., 2005).”
BackgroundOpiate addiction and cocaine addiction: underlying molecular neurobiology and genetics
Kreek, M. J., Levran, O., Reed, B., Schlussman, S. D., Zhou, Y., & Butelman, E. R. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60390 · Cited by 220
“Activation of V1b receptor pathways in the amygdala is an important step in the neurobiology of stress-related behaviors, including anxiogenic and depressive behaviors in rodents (74).”
Oxytocin and vasopressin: powerful regulators of social behavior
Caldwell, H. K. (2017) · The Neuroscientist · doi:10.1177/1073858417708284 · Cited by 216
Behavioral effects of neuropeptides in rodent models of depression and anxiety
Rotzinger, S., Lovejoy, D. A., & Tan, L. A. (2010) · Peptides · doi:10.1016/j.peptides.2009.12.015 · Cited by 211
Elizalde, N., Gil-Bea, F. J., Ramírez, M. J., Aisa, B., Lasheras, B., Del Rio, J., & Tordera, R. M. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1035-1 · Cited by 200
“Among them, increased immobility in the forced swimming test (Tannenbaum et al. 2002; Griebel et al. 2002a, b; Strekalova et al. 2004; Solberg et al. 1999), decreased self-care and grooming (Griebel et al. 2002a, b ;A lonso et al.2004 ;D ucottet et al.2003 ;M ineur et al. 2003) and decreased male aggression (Tannenbau…”
BackgroundMethodResultInfluentialLandgraf, R., Keßler, M. S., Bunck, M., Murgatroyd, C., Spengler, D., Zimbelmann, M., Nußbaumer, M., Czibere, L., Turck, C. W., Singewald, N., et al. (2007) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2006.07.003 · Cited by 199
Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?
Griebel, G., & Holsboer, F. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3702 · Cited by 194
Self-citationYalcin, I., Aksu, F., & Belzung, C. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.03.029 · Cited by 185
Pharmacological treatment of anxiety disorders: Current treatments and future directions
Farach, F. J., Pruitt, L. D., Jun, J. J., Jerud, A. B., Zoellner, L. A., & Roy-Byrne, P. P. (2012) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2012.07.009 · Cited by 183
Agonistic Behavior and Unpredictable Chronic Mild Stress in Mice
Mineur, Y. S., Prasol, D. J., Belzung, C., & Crusio, W. E. (2003) · Behavior Genetics · doi:10.1023/a:1025770616068 · Cited by 179
“Scores were defined as follows (Ducottet et al., 2003; Griebel et al., 2002).”
The vasopressin system — From antidiuresis to psychopathology
Frank, E., & Landgraf, R. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.11.063 · Cited by 179
“Future experiments, utilizing the lately established V1B receptor antagonist SSR149415, which was shown to be anxiolytic in social interactions (Griebel et al., 2002; Shimazaki et al., 2006) and the selective V1B receptor agonist d[Leu(4),Lys(8)]VP (Pena et al., 2007) will help to further clarify…”
MethodBehaviour in the elevated plus-maze predicts coping after subchronic mild stress in mice
Ducottet, C., & Belzung, C. (2004) · Physiology & Behavior · doi:10.1016/j.physbeh.2004.01.013 · Cited by 177
The Vogel conflict test: procedural aspects, γ-aminobutyric acid, glutamate and monoamines
Millan, M. J., & Brocco, M. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01275-5 · Cited by 177
Trends in the Development of New Antidepressants. Is there a Light at the End of the Tunnel?
Pacher, P., & Kecskemeti, V. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043455594 · Cited by 175
Enhanced Long-Term Synaptic Depression in an Animal Model of Depression
Holderbach, R., Clark, K., Moreau, J.-L., Bischofberger, J., & Normann, C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.07.007 · Cited by 174
McGregor, I. S., Callaghan, P. D., & Hunt, G. E. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.132 · Cited by 171
“elicits anxiolytic, antidepressant and prosocial effects (Griebel et al., 2002; Stemmelin et al., 2005; Shimazaki et al., 2006).”
BackgroundInnovative Approaches for the Treatment of Depression: Targeting the HPA Axis
THOMSON, F. J., & Craighead, M. W. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9518-3 · Cited by 171
“, restraint, forced swimming, water deprivation) over a period of 7 weeks, which leads to a reduction in grooming behaviour and worsening of physical appearance as well as behavioural changes such as increase anxiety and a reduced ability to cope with aversive situations [178].”
BackgroundTordera, R. M., Totterdell, S., Wojcik, S. M., Brose, N., Elizalde, N., Lasheras, B., & Del Rio, J. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05259.x · Cited by 169
“VGLUT1 ⁄ – mice showed increased immobility time in this test compared to WT littermates and the increase was similar to that reported in a variety of animal models of depression, including chronic mild stress and transgenic mice models (Solberg et al., 1999; Griebel et al., 2002; Tannenbaum et al., 2002; Strekalova e…”
ResultKeck, M. E., Welt, T., Müller, M. B., Uhr, M., Ohl, F., Wigger, A., Toschi, N., Holsboer, F., & Landgraf, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300040 · Cited by 168
“Most recently, administration of a nonpeptide AVP vasopressin 1b (V1b) receptor antagonist was shown to display anxiolytic and antidepressant-like effects in rodents (Griebel et al, 2002).”
BackgroundFeeling Strained? Influence of Genetic Background on Depression-Related Behavior in Mice: A Review
Jacobson, L. H., & Cryan, J. F. (2007) · Behavior Genetics · doi:10.1007/s10519-006-9106-3 · Cited by 167
Landgraf, R., Frank, E., Aldag, J. M., Neumann, I. D., Sharer, C. A., Ren, X., Terwilliger, E. F., Niwa, M., Wigger, A., & Young, L. J. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02750.x · Cited by 164
“Released centrally from dendrites, cell bodies and axons, arginine vasopressin (AVP) binds to the V1a and V1b receptor (R) subtypes in hypothalamic and limbic brain areas to trigger a variety of behavioural effects (Landgraf, 1995; Griebel et al., 2002; Ludwig et al., 2002).”
BackgroundMurgatroyd, C., Wigger, A., Frank, E., Singewald, N., Bunck, M., Holsboer, F., Landgraf, R., & Spengler, D. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.1614-04.2004 · Cited by 163
“Second, administration of an AVP V1a/b receptor antagonist directly into the PVN of freely behaving HAB rats, via inverse microdialysis, normalized their behavioral peculiarities (Wigger et al., 2004), thus supporting the anxiogenic and depression-inducing potency of the central AVP system (Landgraf et al., 1995; Pitk…”
BackgroundDucottet, C., & Belzung, C. (2004) · Behavioural Brain Research · doi:10.1016/j.bbr.2004.05.018 · Cited by 160
Antidepressant-like effects of melatonin in the mouse chronic mild stress model
Detanico, B. C., Piato, Â., de Freitas, J. J., Lhullier, F. L. R., Hidalgo, M. P. L., Caumo, W., & Elisabetsky, E. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.02.037 · Cited by 156
Chronic Mild Stress (CMS) in Mice: Of Anhedonia, ‘Anomalous Anxiolysis’ and Activity
Schweizer, M., Henniger, M. S. H., & Sillaber, I. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004326 · Cited by 155
“In other studies using the CMS procedure, an increase in immobility in the FST [26–28], decreased grooming [23], altered performance in cognitive tasks [29] as well as changes in anxiety-like behaviour [20,24] were observed.”
MethodCopper-Catalyzed Oxoazidation and Alkoxyazidation of Indoles
Yin, H. H., Wang, T., & Jiao, N. (2014) · Organic Letters · doi:10.1021/ol500793c · Cited by 155
Beech, A. R., & Mitchell, I. (2004) · Clinical Psychology Review · doi:10.1016/j.cpr.2004.10.002 · Cited by 155
“The neuropeptide oxytocin and vasopressin systems can interact with the corticosteroid system (Griebel et al., 2002; Legross, 2001).”
BackgroundLearning and memory impairments in a neuroendocrine mouse model of anxiety/depression
Darcet, F., Mendez‐David, I., Tritschler, L., Gardier, A. M., Guilloux, J., & David, D. J. P. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00136 · Cited by 154
“This measure has been described as a reliable and well-validated index of a depressed-like state (Griebel et al., 2002; Santarelli et al., 2003).”
BackgroundChronic mild stress generates clear depressive but ambiguous anxiety-like behaviour in rats
Kompagne, H., Bárdos, G., Szénási, G., Gacsályi, I., Hársing, L. G., & Lévay, G. I. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.06.008 · Cited by 153
Autoantibodies against neuropeptides are associated with psychological traits in eating disorders
Fetissov, S. O., Harro, J., Jaanisk, M., Järv, A., Podar, I., Allik, J., Nilsson, I., Sakthivel, P., Lefvert, A. K., & Hökfelt, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507204102 · Cited by 152
Vancassel, S., Leman, S., Hanonick, L., Denis, S., Roger, J., Nollet, M., Bodard, S., Kousignian, I., Belzung, C., & Chalon, S. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700328-jlr200 · Cited by 149
“This method has been validated in a number of recent studies (31, 32, 35).”
MethodWersinger, S. R., Caldwell, H. K., Christiansen, M., & Young, W. S. (2006) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2006.00294.x · Cited by 148
“Pharmacological antagonism of the Avpr1b also has behavioral consequences, producing reduced anxiety and aggression (Griebel et al. 2002; Blanchard et al. 2005; Stemmelin et al. 2005).”
BackgroundReduced ultrasonic vocalizations in vasopressin 1b knockout mice
Scattoni, M. L., McFarlane, H. G., Zhodzishsky, V., Caldwell, H. K., YOUNG, W., Ricceri, L., & Crawley, J. N. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.09.034 · Cited by 146
“Treatment with Avpr1b antagonists produced anxiolytic and antidepressant effects in rodents [16,18].”
BackgroundThe Central Vasopressinergic System: Examining the Opportunities for Psychiatric Drug Development
Ring, R. H. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053382241 · Cited by 145
Bonne, O. B., Grillon, C., Vythilingam, M., Neumeister, A., & Charney, D. S. (2004) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2003.12.001 · Cited by 145
An Assessment of Anxiolytic Drug Screening Tests: Hormetic Dose Responses Predominate
Calabrese, E. J. (2008) · Critical Reviews in Toxicology · doi:10.1080/10408440802014238 · Cited by 142
“In such testing, hormetic-like dose responses were also reported with similar quantitative features of the doseresponse relationship (Kilfoil et al., 1989; Griebel et al., 2002a, 2002b).”
BackgroundResultZink, C. F., Stein, J. L., Kempf, L., Hakimi, S., & Meyer‐Lindenberg, A. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.4899-09.2010 · Cited by 140
“, 2007), and pharmacological antagonism of neural vasopressin receptors (Griebel et al., 2002; Ferris et al., 2006; Bleickardt et al., 2009), which link vasopressin with the enhancement of fear, anxiety, and aggression.”
BackgroundMultifaceted strain-specific effects in a mouse model of depression and of antidepressant reversal
Ibargüen-Vargas, Y., Surget, A., Touma, C., Palme, R., & Belzung, C. (2008) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2008.07.010 · Cited by 136
Neurohypophyseal hormones manipulation modulate social and anxiety-related behavior in zebrafish
Braida, D., Donzelli, A., Martucci, R., Capurro, V., Busnelli, M., Chini, B., & Sala, M. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2482-2 · Cited by 134
“Reduced anxiety was shown in mice treated with the selective AVP1b subtype receptor antagonist SSR149415 (Griebel et al. 2002; Blanchard et al. 2005; Stemmelin et al. 2005).”
BackgroundOxytocin, vasopressin, and the motivational forces that drive social behaviors
Caldwell, H. K., & Albers, H. E. (2015) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2015_390 · Cited by 129
The vasopressin Avpr1b receptor: Molecular and pharmacological studies
Roper, J. A., O'Carroll, A.-M., Young, W. S., & Lolait, S. (2010) · Stress · doi:10.3109/10253890.2010.512376 · Cited by 130
“…(e.g. olfactory bulbectomy, Flinder’s sensitive line) that are used to determine the efficacy of potential antidepressant and anxiolytic drugs (Griebel et al. 2002; Overstreet and Griebel 2005; Stemmelin et al. 2005; Louis et al. 2006; Salomé et al. 2006; Shimazaki et al. 2006; Hodgson et…”
BackgroundMethodInfluentialKlein, L. C., & Corwin, E. J. (2002) · Current Psychiatry Reports · doi:10.1007/s11920-002-0072-z · Cited by 128
Kasper, S. F., & Hamon, M. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970902717024 · Cited by 127
“Key words: Agomelatine, major depressive disorder, melatonergic receptors, 5-HT2C receptors”
BackgroundKeck, M. E., Kern, N., Erhardt, A., Unschuld, P. G., Ising, M., Salyakina, D., Müller, M. B., Knorr, C. C., Lieb, R., Hohoff, C., et al. (2008) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30750 · Cited by 125
“A plethora of preclinical data points to the corticotropin releasing hormone (CRH) and vasopressin (AVP) systems as two of the major peptidergic candidate systems involved in these disorders [Antoni, 1993; Griebel et al., 2002; Keck et al., 2002, 2003; Müller et al., 2002].”
BackgroundStemmelin, J., Cohen, C., Terranova, J.-P., Lopez‐Grancha, M., Pichat, P., Bergis, O. E., Decobert, M., Santucci, V., Françon, D., Alonso, R., et al. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301424 · Cited by 125
“The protocol consists of the sequential and unpredictable application of a variety of mild stressors (for example, restraint, forcedswimming, water and/or food deprivation) during 6 weeks (Griebel et al, 2002a, b).”
BackgroundMethodSelf-citationArakawa, H., Arakawa, K., & Deak, T. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.10.013 · Cited by 125
Bui, T., Hernández‐Torres, G., Milite, C., & Barbas, C. F. (2010) · Organic Letters · doi:10.1021/ol102493q · Cited by 124
Gal, C. S., Wagnon, J., Tonnerre, B., Roux, R., Garcia, G., Griebel, G., & Aulombard, A. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2005.tb00035.x · Cited by 124
Self-citationBorn to be anxious: neuroendocrine and genetic correlates of trait anxiety in HAB rats
Landgraf, R., & Wigger, A. (2003) · Stress · doi:10.1080/1025389031000104193 · Cited by 122
“In this context, it is of note that not only AVP (Landgraf et al., 1995; Liebsch et al., 1996; Pitkow et al., 2001; Griebel et al., 2002) but also CRH (Arborelius et al., 1999; Keck et al., 2001b; Heinrichs et al., 2002; Van Gaalen et al., 2002) and oxytocin (Windle et al., 1997; Neumann et al.,…”
Background
Metadata
- Authors
- Griebel, G., Simiand, J., Serradeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J.-P., & Soubrié, P.
- Affiliations
- Sanofi (France) (FR)
- Sanofi–Synthelabo Recherche, Avenue P. V.-Couturier, 92220 Bagneux, France; Sanofi–Synthelabo Recherche, Route d'Espagne, 31100 Toulouse, France; and Sanofi–Synthelabo Recherche, Rue du Professeur Blayac, 34000 Montpellier, France
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2002-04-16
- Volume
- 99
- Issue
- 9
- Pages
- 6370-6375
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC122955
- OpenAlex
- W2003547326
- Cited by
- 471
- References
- 31
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 6 · 2023: 6 · 2022: 8 · 2021: 12 · 2020: 14 · 2019: 10 · 2018: 15 · 2017: 8 · 2016: 20 · 2015: 18 · 2014: 29 · 2013: 16 · 2012: 21
- FWCI
- 10.11
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroendocrine regulation and behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- non-peptide antagonists, anxiolytic effects, antidepressant effects, anxiety, depression, chronic mild stress, social defeat, traumatic stress, emotional processing, hypophysectomy, mood disorders
- MeSH terms
- Animals, Antidepressive Agents, Antidepressive Agents, Tricyclic, Anxiety, Behavior, Animal, Depression, Feeding Behavior, Fluoxetine, Imipramine, Indoles, Kinetics, Male, Mice, Inbred BALB C, Pyrrolidines, Stress, Physiological, Stress, Psychological, Time Factors, Anti-Anxiety Agents, Rats, Sprague-Dawley, Rats, Wistar, Risk Assessment, Antidepressive Agents, Second-Generation, Mice, Rats, Antidiuretic Hormone Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.